On October 7, 2019, California became the first state to enact legislation— Assembly Bill 824 (“AB 824”)—rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive. [1] This alert provides a brief summary of some of the key provisions as written; the final implications of this statute await judicial review. Reverse Payment Settlements Including “Anything of Value” Presumed Illegal The settlement agreements subject to the new law, sometimes referred to pejoratively as “reverse payment” or “pay for delay” agreements, typically resolve Hatch-Waxman patent litigation [2] in which a generic pharmaceutical manufacturer has challenged a patent covering a brand pharmaceutical manufacturer’s drug product, and in which a plaintiff or government enforcer
Share on
|
|
The US State of California becomes the first State to enact legislation rendering certain pharmaceutical patent litigation settlement agreements presumptively anticompetitive
This article has been nominated for the 2020 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards.
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.
